Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study
全人抗肿瘤坏死因子 α 单克隆抗体阿达木单抗 (D2E7) 对 DMARD 难治性类风湿关节炎患者的疗效和安全性：一项为期 12 周的 II 期研究
期刊:Annals of the Rheumatic Diseases
影响因子:20.3
doi:10.1136/ard.2003.009563
L B A van de Putte, R Rau, F C Breedveld, J R Kalden, M G Malaise, P L C M van Riel, M Schattenkirchner, P Emery, G R Burmester, H Zeidler, H M Moutsopoulos, K Beck, H Kupper
